A common anti-malaria drug, Hydroxychloroquine, is being tested by the FDA as a possible treatment for COVID-19.
China, South Korea and France have all shown positive results when using it to treat patients. So far, it has been shown to clear the upper respiratory tract of the virus in 3-6 days, compared to 20 or more days without treatment. It reduces the duration and symptoms of COVID-19 by disrupting all processes of the virus and inactivating the body's immune response.
Hydroxychloroquine has been around for decades, is well studied, and is low-cost. It is also used to treat Lupus, Rheumatoid Arthritis, Sjogren's disease and Lyme disease. The FDA has expedited live clinical trials in the United States and other trials are underway around the world.